Genmab A/S (GNMSF)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from GNMSF's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Genmab A/S's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $10.1B | $8.4B | $14.5B | $16.5B | $21.5B |
| Net income | $4.8B | $3.0B | $5.5B | $4.4B | $7.8B |
| Free cash flow | $6.1B | $2.0B | $3.6B | $7.0B | $7.5B |
| EPS (diluted) | $72.21 | $44.77 | $82.59 | $66.02 | $121.36 |
| Operating margin | 62.4% | 35.1% | 43.2% | 32.3% | 31.1% |
Where the revenue comes from
Revenue by regions, fiscal 2025.
Superinvestors who own GNMSF
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by Genmab A/S's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when GNMSF trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
Are Genmab A/S insiders buying the stock?
No open-market insider purchases of GNMSF in the last 12 months, according to SEC Form 4 filings.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.